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Anatomy of clinical consultation. 
Pain in a patient with metastasized 
prostate cancer. I can help when 
you ask me the right questions
Abstract
We are all asked for consultations to see a complex patient or to answer the telephone call and think about 
the patient without seeing him and without  touching him. Although this type of consultation is much 
cheaper, faster and sometimes effective. There is a danger that we hear only a part of the story, or a story 
coloured in such a way that it will push the decision in one direction, intended by a doctor or nurse who 
requested it. In this article I describe a consultation “by a telephone”. I go in de depths of the request and 
discuss with the doctor who asked me in consultation all pros and cons. I come to conclusion that we should 
teach young doctors how to request consultation, which questions to ask without suggesting the answers.
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Introduction
I was asked to advice on pain control concerning 
an elderly patient with prostate cancer. This induced 
very interesting discussions on which I shall reflect 
here. Pain control in patients with prostate cancer 
is often difficult and some aspects of it are con-
troversial. This case shows how important it is to 
gather right information before asking somebody 
for advice. Gathering this information only may 
help to solve the problem. It also helps to reflect 
on the case with the colleagues and the nurses, 
providing you can separate the clinical facts from 
your emotions and feelings. Here I present exact 
case description as I received it. 
Case description
The patient was a 72 years old man. He was diag-
nosed 9 years ago with prostate cancer and known 
for 18 months with multiple bone metastases. He 
suffered of severe pain which in the initial presenta-
tion was named “bone pain”. Initially the pain re-
sponded well to fentanyl 25 mcg/hour patch. It went 
so good, that the patient started slowly to decrease 
the dose himself, while the patch was well tolerated. 
However, after couple of weeks the pain intensity 
increased, and it was presumed by the presenting 
doctor that this resembled tumour progression. 
However, no information on the changes in bone 
scyntygraphy or prostate specific antigen (PSA) 
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were given. The dose of fentanyl was thus gradually 
increased to 100 mcg/hour every 3 days. Because 
of progressive weight loss in the last 3 weeks the 
patient was prescribed prednisone to stimulate 
his appetite and gain some energy. On the other 
hand it was hoped that prednisone may contrib-
ute to better analgesia, which it did not. At the 
moment of consultation the patient was still suf-
fering of severe pain with frequent exacerbations, 
called by the presenter “breakthrough pain”. He 
used up to 3 PRN doses of oral morphine 40 mg, 
but without much effect. Besides, he complained 
of breathlessness, again this was presumed to be 
due to “lung metastases”, but no diagnostic imag-
ing was performed. The dose of fentanyl was in-
creased again to 125 mcg/hour, but to no avail. The 
patient became restless, could not concentrate or 
sleep at night and was dozing off during the day 
time. His daughter observed that especially in the 
evening, he was confused. There was no cognitive 
impairment diagnosed before.
Patients’ medication
1. Monthly 90 mg of pamidronate IV
2. Metoclopramide 10 mg tds
3. Prednisone 10 mg od
4. Lactulose syrup 50% 20 ml od
The question asked me was: Would opioid rota-
tion be appropriate? To which drug and which dose? 
Would fentanyl buccal or intranasal be a good choice 
for the patient’s breakthrough pains?
Questions that need to be asked
To answer these questions we need to have some 
more information. It should be possible to obtain 
this information from the doctor who requested 
this consultation. It would be much easier, when 
the doctor asking for consultation would have the 
answers ready. However, as it frequently happens, 
the doctors who gather these facts  properly, do not 
need a consultation... On the other hand many doc-
tors who ask for consultation do not like to admit 
they do not know something about their patients and 
they try to mask it or even confabulate the truth. 
Another problem is going through the assumptions, 
like in the case above. 
The case presented to me was without any de-
tails of the oncological history of this patient. It 
looked like it is not important to a doctor working 
in palliative medicine. How advanced was the tu-
mour initially? How was the patient treated? Did he 
have locally advanced cancer treated with prostatec-
tomy and/or radiotherapy. Initial therapy, especially 
when tumours are less advanced can be radical and 
survivors may suffer of many iatrogenic damage 
(a.e. neuropathy).
Was there any radiotherapy given for the bone 
pain already? Where? With what effect? We know 
the patient has bone metastases, but can we review 
his most recent bone scytygraphy? Where does the 
patient localise exactly his (worst) pain? Do these 
localisations match with the findings on the bone 
scan? This is essential for the diagnosis of the “bone 
pain”. Bone scyntygrams should be performed twice 
a year and progression of metastases (or their regres-
sion) should be monitored. Lack of match between 
complains and bone scyntygraphy suggest exraosseal 
source of pain (see below)
Are there any bones instable (hips, pelvis)? Is the 
pain getting worse on movement or at rest? What 
is the dynamics of PSA increase (if any) in comparison 
to increase of pain? Does this patient presents with 
diffuse skin hyperalgesia and/or allodynia, or lo-
calised mechanoreceptive pain (pain on pressure). 
Patients with prostate cancer live much longer than 
decades ago and they run the risk of developing 
many other than “malignant” pains. Among them 
is the osteoporosis, bone instability and fractures. 
Sometimes not to be seen on scyntygrams. Here we 
should have a plain X rays. Typically the “instability” 
of pain are focal and are not accompanied by the 
PSA rise. In comparison to the bone pain due to 
metastases growing in the bones, the sites are also 
sensitive to movement and palpation.
Is the patient constipated due to the opioids? 
On rare occasions patients may have no analgesia 
from opioids, but also may be not constipated. Rota-
tion to another opioid, may solve the problem (and 
cause constipation). Here we have an indirect and 
imprecise information that the patient uses lactulose 
syrup. No precise information about the defecation 
pattern is presented.
What does it mean that the patient has a break-
through pains? Is the pain in general well controlled 
and the patient experiences sudden (on movements?) 
exacerbations? Is there any radiation of pain or lo-
calized hyperalgesia area suggesting nerve or nerve 
root compression? This is very important as “break-
through pains” are defined as pains against the 
background of well controlled pain. 
We were told the patient was prescribed mor-
phine orally, 40 mg PRN. Was there any response to 
the PRN doses after administration? We were told 
that the patient was still in pain, but the response 
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to oral morphine was poor, but this was not speci-
fied enough. 
Were there laboratory tests done, especially the 
renal function, plasma electrolytes including Mg++ 
and Ca++ and full blood count are of importance 
for pain control. 
Differential diagnosis
The differential diagnosis is a summary of clini-
cal thinking and answering the above questions. 
Answering the clinical questions one may make one 
possibility more probable than the other. 
1. Pain due to bone metastases. This pain is usu-
ally worse at rest. Sometimes patients report 
that the pain is getting less during the move-
ment. The pain is usually not mechanoreceptive, 
this means it will not increase on pressuring with 
finger. Progression of pain would coincide with 
hormonal unresponsiveness and progression of 
the PSA. By itself this pain responds well to com-
bination of opioids and if possible paracetamol 
and/or NSAID. 
2. Pain due to bone instability, especially of the 
hips and lumbar spine. This pain is getting worse 
on movement and on weight bearing. It is get-
ting less at night while resting in bed. The patient 
may even have discrete bone fractures which 
should be diagnosed with X rays. The instable 
or fractured sites may be sensitive to pressure 
(mechanoreceptive pain). The pain due to bone 
fractures may be associated with a neuropathic 
pain (see below). Due to iatrogenic hypogonad-
ism and many years of anti-androgen therapy, 
the patient could suffer osteoporosis and bone 
instability or fractures. The pain due to oste-
oporosis and fractures is usually not associated 
with rising PSA.
3. Pain due to bone metastases that cause com-
pression of the nerve roots (hyperalgesia of 
the dermatomal distribution) or peripheral 
nerves (hyperalgesia in discrete areas served by 
the nerves). However, most of the peripheral 
nerve compression is of not “malignant”origin. 
It depends on general deterioration, loss of tissue 
supporting and protecting nerves, compression 
against bones etc. Also, typically, this pain is not 
associated with the PSA rise.
4. Pain due to the opioids themselves; the so called 
opioid-induced hyperalgesia (OIH). This pain 
would be indeed diffuse, would not be explained 
by anatomical changes (negative match between 
the complains and bone scan findings). The dy-
namics of this pain may be unrelated to the 
increase of PSA. It would be important here to 
know the renal function as some metabolites of 
morphine may accumulate in renal insufficiency 
and may provoke neurotoxicity. Also fentanyl 
is the most OIH-genic opioid, in comparison to 
methadone or buprenorphine.
5. The pain may be related to dietary deficien-
cies as the patient is cachexic and is not eating 
well. Among the most important is hypomag-
nesaemia, which can present as an increasing 
insensitivity to the opioids. Magnesium increas-
es opioid binding to mu receptors [1]. Previ-
ous chemotherapy including cis-platin may be 
responsible for renal function impairment but 
also for magnesium loosing nephropathy [2].
6. If the pain intensity is increasing at the third day 
of the patch, this would suggest that fentanyl 
is rapidly absorbed from the patch and/or rapidly 
metabolised and the patch becomes “empty” at 
the third day. This can be easily seen when the 
frequency of the oral morphine PRN medica-
tion is analysed in time. The need for additional 
doses is clustered at the third day of the patch. 
However, this phenomenon occurs usually with 
the reservoir patches, but is much less often seen 
with the new matrix patches. This phenomenon 
is called “end-of-dose” pain and can be even 
defined as pseudoaddiction. 
Discussion
Many patients, nearly automatically, would as-
sume that the pain suffered by this patient is a typi-
cal “cancer pain”. However, this patient, thanks to 
the modern oncological treatment, lives so much 
longer than decades ago, that it is probable that 
he suffers also other, “non-malignant pain” like 
osteoporosis, bone instability, nerve compression or 
opioid induced hyperalgesia. Most of these “non-ma-
lignant” pains share couple of characterictics. They 
may be less opioid sensitive than pain due to bone 
metastases and the patients easily develop toler-
ance when the pain is treated with opioids only. 
Patients may present with toxic effects of opioids, 
while being still in pain.
This is also the reason, why the pain should 
be diagnosed and treated specifically with multi-
ple modalities, not only with opioids. This patient, 
I understood was at home and refused any other 
diagnostic procedures and visits to hospital special-
ists. However, generic treatment with opioids, with 
or without adjuvant drugs is highly improbable to 
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help here. Gathering right information should be 
an on-going process. Severe pain, many trials and 
changes of medication, may demotivate patient to 
do anything and push the doctor into the scenario 
of “generic pain” treatment.
Switch to other opioids would help for a short 
while. However, nothing is suggesting that the pa-
tient is actually dying and his prognosis may be 
weeks or even months. So the question the doctor 
should ask is not to which opioid he should switch, 
but what is the diagnosis of pain and are there any, 
non-invasive, ways to get the diagnosis as sharp 
as possible and start specific treatment.
This case also shows how much are we influ-
enced by the Industry and their advertisements on 
new and improved drugs. Many “breakthrough 
pains” are in reality poorly diagnosed and controlled 
pains. Treatment of these pains with the modern 
rapid acting fentanyl preparations will probably 
affect only the budget of your institution, but will 
not help the patient.
What do we need to think of prednisone treat-
ment? Prednisone treatment is often used as an 
adjuvant in the treatment of hormone escaped 
prostate cancer. There is good evidence saying 
that in such patients there is still some additional 
anti-androgen effect, by addressing a different 
route of androgen metabolism [3–5]. Corticoster-
oids may increase patient’s appetite, but they are 
at the same time katabolic and provoke nitrogen 
losses [6]. In the longer term this results in poorer 
patient’s condition and mobility. Prednisone can 
be used as adjuvant in pain treatment like in liver 
capsule tension, but none of this was specified in 
patients’ history. Again, using such a “generic” drug 
for the unspecified symptoms will probably not 
help, but only trouble the view and interpretation 
of clinical facts.
Why is the pain control in prostate cancer typically 
a big problem? One of the reasons for this is iatro-
genic hypogonadism. Longstanding  antiandrogen 
therapy is not only responsible for muscle wasting, 
poor appetite and fatigue, but also for decreased 
pain threshold. Substitution with testosterone, fea-
sible in all other non-hormone dependent cancers, 
is not possible here. Unfortunately.
In truely “bone pain” due to metastases the 
treatment of choice is radiotherapy. Opioids and 
adjuvants are only a bridge to analgesia resulting 
from radiotherapy. In bone instability pain the pa-
tient should be consulted with orthopaedic surgeon 
and bone scan and plain films should be carefully 
examined. In many cases bone instability can be 
treated operatively. Fractures of the vertebrae can 
be treated with vertebroplasty [7].
Conclusion
The intention of this article was not to solve the 
problem of this patient but to show the complexity 
of the case and a structure for step-by-step solution 
to the problem. Crucial here is gathering clinical 
facts, abstinence from assumptions and formulat-
ing and asking clear and specific questions. Without 
this process, a consultation by an experienced col-
league may prove to be useless.
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